Form 4: KKR Sells 6 Million Shares of BridgeBio Pharma (BBIO) in Block Trade

KKR Genetic Disorder L.P. sold 6 million shares of BridgeBio Pharma at $32.96 per share.

Summary

• KKR Genetic Disorder L.P. sold 6,000,000 shares of BridgeBio Pharma, Inc. common stock on March 5, 2025.
• The sale was executed at a price of $32.96 per share.
• The transaction was conducted as a block sale pursuant to Rule 144 of the Securities Act of 1933.
• Following the transaction, KKR Genetic Disorder L.P. indirectly holds 19,260,971 shares.
• Various KKR entities and individuals, including KKR Genetic Disorder GP LLC, KKR Group Partnership L.P., KKR Group Holdings Corp., KKR Group Co. Inc., KKR & Co. Inc., KKR Management LLP, Henry R. Kravis, and George R. Roberts, are associated with the reporting entity.
• These reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The document is a standard SEC filing related to a stock sale. The sentiment is neutral as it simply reports a transaction. The size of the sale could be seen as slightly negative.

Management Comments

• Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities.
• Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein.

Industry Context

This transaction represents a significant block trade of shares in a publicly traded biopharmaceutical company, BridgeBio Pharma. Such transactions can influence market sentiment and stock price, particularly when executed by a major shareholder like KKR.

Stakeholder Impact

• The sale of a large block of shares could potentially impact the share price of BridgeBio Pharma, affecting current shareholders.
• The transaction may influence market perception of the company's prospects.

Key Dates